Scaffold-stabilized L2 peptides as HPV vaccine (P-824)

**Key facts**
- simple production in *E. coli*
- increased titer of neutralizing antibodies
- cross-immunity against other cancerogenic HPV strains

**Abstract**
Cervical cancer is women's second most frequent cancer worldwide with an estimated 500,000 cases and approx. 250,000 deaths per year. It has been established that infection with certain ("high-risk") types of human Papillomaviruses (HPV) is the most important risk factor for the development of cervical cancer. Two vaccines which are commercially available were developed based on the HPV L1 protein. There are, however, some drawbacks to these L1-based vaccines: the immune reaction against L1 is mostly type-specific, meaning that there is hardly any cross-protection against HPV types that were not included in the vaccine. Also, the L1 vaccines have to be produced either in yeast or in insect cells, which makes production cost-intensive.

Our international team of researchers has come a huge step closer to a solution of these problems: the thioredoxin-L2 vaccine can be produced in standard *E. coli* bacteria, which makes a cost-effective production feasible. Moreover, immunization against peptides from the L2 protein gives a robust immune reaction that provides cross-protection against a variety of other high-risk HPV strains.

**Development Stage**
Scaffold-stabilized L2-vaccines have been produced and their efficacy has been shown in animal models.

**The Technology**
The thioredoxin-L2 vaccines consist of thioredoxin as a "scaffold" protein and one of several L2 peptide concatamers. The most effective peptides have been identified by epitope mapping; a positive correlation of the number of peptide units in the concatamer with the titer of neutralizing antibodies has been shown.

**Applications and Commercial Opportunity**
The proteins can be used as a vaccine to induce immunity against HPV primary infection (preventive vaccination), which can be used against a variety of high-risk HPV strains.

**Inventors**
The investigators are: Martin Müller and Ivonne Rubio, DKFZ Heidelberg, Germany, Massimo Tommasino, IARC, Lyon, France, and Simone Ottonello and Angelo Bolchi, University of Parma, Italy.

**Intellectual Property**
A priority patent application “Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or fragment thereof” EP 2199301 was filed December 19, 2008. A subsequent PCT was published as WO 2010/070052, which was nationalized as EP 09795419.2 and US 2011/0293621.

**Reference**

**DKFZ Contact:**
Dr. Christian Kliem  
Deutsches Krebsforschungszentrum  
Technology Transfer Office T010  
Email: c.kliem@dkfz.de  
Tel.: +49-(0)6221-42-2948  
Fax: +49-(0)6221-42-2956